Technology Bundle ID
TAB-3254

Protein Nanoparticles for Antigen Display in Vaccines

Linked ID
E-005-2017-0
Lead Inventors
Audray Harris (NIAID)
Co-Inventors
Dustin McCraw (NIAID)
Therapeutic Areas
Infectious Disease
ICs
NIAID
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Commercial Applications
  • Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine
Competitive Advantages
  • The nanoparticles may be disassembled and re-assembled allowing mixing of antigens
  • Expression in prokaryotic and eukaryotic systems
  • Avoids production and usage of live viruses for vaccine generation
  • Effective immune response due to the use of authentic viral antigens
  • Stability of particle and immunogenicity after high temperature exposure
  • Incorporation of epitopes from group 1 and group 2 influenza viruses
  • Broadly neutralizing antibodies against influenza virus

Request More Info

Licensing Contact: